JP2021501754A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2021501754A5 JP2021501754A5 JP2020524155A JP2020524155A JP2021501754A5 JP 2021501754 A5 JP2021501754 A5 JP 2021501754A5 JP 2020524155 A JP2020524155 A JP 2020524155A JP 2020524155 A JP2020524155 A JP 2020524155A JP 2021501754 A5 JP2021501754 A5 JP 2021501754A5
- Authority
- JP
- Japan
- Prior art keywords
- optionally substituted
- integrin ligand
- alkyl
- αvβ6 integrin
- epithelial cells
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Priority Applications (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2023060316A JP7758699B2 (ja) | 2017-11-01 | 2023-04-03 | インテグリンリガンドおよびその使用 |
| JP2025107419A JP2025129221A (ja) | 2017-11-01 | 2025-06-25 | インテグリンリガンドおよびその使用 |
Applications Claiming Priority (7)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201762580398P | 2017-11-01 | 2017-11-01 | |
| US62/580,398 | 2017-11-01 | ||
| US201862646739P | 2018-03-22 | 2018-03-22 | |
| US62/646,739 | 2018-03-22 | ||
| US201862679549P | 2018-06-01 | 2018-06-01 | |
| US62/679,549 | 2018-06-01 | ||
| PCT/US2018/058471 WO2019089765A1 (en) | 2017-11-01 | 2018-10-31 | Integrin ligands and uses thereof |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2023060316A Division JP7758699B2 (ja) | 2017-11-01 | 2023-04-03 | インテグリンリガンドおよびその使用 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2021501754A JP2021501754A (ja) | 2021-01-21 |
| JP2021501754A5 true JP2021501754A5 (enExample) | 2021-12-09 |
| JP7445594B2 JP7445594B2 (ja) | 2024-03-07 |
Family
ID=66332633
Family Applications (3)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2020524155A Active JP7445594B2 (ja) | 2017-11-01 | 2018-10-31 | インテグリンリガンドおよびその使用 |
| JP2023060316A Active JP7758699B2 (ja) | 2017-11-01 | 2023-04-03 | インテグリンリガンドおよびその使用 |
| JP2025107419A Pending JP2025129221A (ja) | 2017-11-01 | 2025-06-25 | インテグリンリガンドおよびその使用 |
Family Applications After (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2023060316A Active JP7758699B2 (ja) | 2017-11-01 | 2023-04-03 | インテグリンリガンドおよびその使用 |
| JP2025107419A Pending JP2025129221A (ja) | 2017-11-01 | 2025-06-25 | インテグリンリガンドおよびその使用 |
Country Status (22)
| Country | Link |
|---|---|
| US (2) | US11597701B2 (enExample) |
| EP (1) | EP3703700A4 (enExample) |
| JP (3) | JP7445594B2 (enExample) |
| KR (2) | KR20250021615A (enExample) |
| CN (1) | CN111526880A (enExample) |
| AU (2) | AU2018359515B2 (enExample) |
| CA (1) | CA3079402A1 (enExample) |
| CL (1) | CL2020001125A1 (enExample) |
| CR (1) | CR20200178A (enExample) |
| EC (1) | ECSP20028090A (enExample) |
| IL (1) | IL274300B2 (enExample) |
| JO (1) | JOP20200102B1 (enExample) |
| MX (2) | MX2020004554A (enExample) |
| MY (1) | MY208467A (enExample) |
| PE (1) | PE20200938A1 (enExample) |
| PH (1) | PH12020550263A1 (enExample) |
| SA (1) | SA520411899B1 (enExample) |
| SG (1) | SG11202002967SA (enExample) |
| TN (1) | TN2020000059A1 (enExample) |
| TW (2) | TWI825039B (enExample) |
| UA (1) | UA128250C2 (enExample) |
| WO (1) | WO2019089765A1 (enExample) |
Families Citing this family (26)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| TN2019000308A1 (en) | 2017-07-06 | 2021-05-07 | Arrowhead Pharmaceuticals Inc | RNAi AGENTS FOR INHIBITING EXPRESSION OF ALPHA-ENaC AND METHODS OF USE |
| US12065458B2 (en) | 2018-02-17 | 2024-08-20 | Arrowhead Pharmaceuticals, Inc. | Trialkyne linking agents and methods of use |
| TW202130809A (zh) | 2019-10-29 | 2021-08-16 | 美商愛羅海德製藥公司 | 用於抑制β-ENaC表現之RNAi藥劑、其組合物及使用方法 |
| CN114058623B (zh) * | 2020-08-06 | 2023-12-12 | 中国科学院化学研究所 | 一种核酸适体识别并结合整合素α3亚基及其相关功能 |
| MX2023002939A (es) * | 2020-09-11 | 2023-04-11 | Arrowhead Pharmaceuticals Inc | Plataformas para el transporte de farmacos hacia el musculo esqueletico y metodos de uso. |
| WO2022056269A1 (en) * | 2020-09-11 | 2022-03-17 | Arrowhead Pharmaceuticals, Inc. | Skeletal muscle delivery platforms and methods of use |
| AU2021342155A1 (en) * | 2020-09-11 | 2023-04-13 | Arrowhead Pharmaceuticals, Inc. | RNAi agents for inhibiting expression of DUX4, compositions thereof, and methods of use |
| WO2022056286A1 (en) * | 2020-09-11 | 2022-03-17 | Arrowhead Pharmaceuticals, Inc. | Integrin targeting ligands and uses thereof |
| WO2022216920A1 (en) | 2021-04-08 | 2022-10-13 | Arrowhead Pharmaceuticals, Inc. | Rnai agents for inhibiting expression of receptor for advanced glycation end-products, compositions thereof, and methods of use |
| BR112023024615A2 (pt) * | 2021-05-28 | 2024-02-20 | Arrowhead Pharmaceuticals Inc | Agentes de rnai para inibir expressão de mucina 5ac (muc5ac), composições dos mesmos, e métodos de uso |
| MX2024004912A (es) * | 2021-10-22 | 2024-05-06 | Arrowhead Pharmaceuticals Inc | Agentes de arni para inhibir la expresion de la metaloproteinasa de matriz 7 (mmp7), composiciones de los mismos y metodos de uso. |
| KR20250120424A (ko) * | 2022-12-14 | 2025-08-08 | 알닐람 파마슈티칼스 인코포레이티드 | 간외 전달을 위한 알파-v 베타-6(αvβ6) 인테그린 리간드 |
| MX2025014897A (es) * | 2023-06-13 | 2026-02-03 | Tuojie Biotech Shanghai Co Ltd | Arnip dirigido a mmp7, conjugado de arnip y su uso medico |
| CN121399119A (zh) * | 2023-06-19 | 2026-01-23 | 广东众生睿创生物科技有限公司 | 一种整合素配体及其用途 |
| CN121586578A (zh) | 2023-08-24 | 2026-02-27 | 上海拓界生物医药科技有限公司 | 靶向RAGE的RNAi剂及其医药用途 |
| TW202516008A (zh) | 2023-09-27 | 2025-04-16 | 大陸商上海拓界生物醫藥科技有限公司 | 含三唑基化合物、製備方法及用途 |
| WO2025067433A1 (zh) | 2023-09-28 | 2025-04-03 | 云合智药（苏州）生物科技有限公司 | 靶向整合素的化合物及其在RNAi剂中的应用 |
| CN122374041A (zh) * | 2023-12-12 | 2026-07-10 | 伊莱利利公司 | 新型治疗递送部分及其用途 |
| CN122270455A (zh) * | 2023-12-22 | 2026-06-23 | 北京炫景瑞医药科技有限公司 | 一种靶向整合素αvβ6的配体、缀合物、组合物以及它们的用途 |
| CN120309684A (zh) * | 2024-01-15 | 2025-07-15 | 武汉人福创新药物研发中心有限公司 | 靶向化合物及其用途 |
| WO2025152967A1 (zh) * | 2024-01-15 | 2025-07-24 | 武汉人福创新药物研发中心有限公司 | 靶向αvβ6的化合物及其用途 |
| WO2025180458A1 (zh) * | 2024-03-01 | 2025-09-04 | 长春金赛药业有限责任公司 | 整联蛋白配体及其用途 |
| WO2025252118A1 (zh) * | 2024-06-06 | 2025-12-11 | 苏州瑞博生物技术股份有限公司 | 整联蛋白αvβ6特异性配体化合物、缀合物、药物组合物及其用途 |
| TW202615058A (zh) * | 2024-06-12 | 2026-04-16 | 美商艾拉倫製藥股份有限公司 | 失養強直性肌肉蛋白質激酶（ｄｍｐｋ）ｉｒｎａ組成物及其使用方法 |
| WO2025261536A1 (zh) * | 2024-06-21 | 2025-12-26 | 长春金赛药业有限责任公司 | 一种整联蛋白配体关键中间体及其制备方法 |
| WO2026061476A1 (zh) * | 2024-09-19 | 2026-03-26 | 长春金赛药业有限责任公司 | 一种多簇连接子、其制备方法及应用 |
Family Cites Families (25)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4522811A (en) | 1982-07-08 | 1985-06-11 | Syntex (U.S.A.) Inc. | Serial injection of muramyldipeptides and liposomes enhances the anti-infective activity of muramyldipeptides |
| DE19831710A1 (de) | 1998-07-15 | 2000-01-20 | Merck Patent Gmbh | Diacylhydrazinderivate |
| CA2371824A1 (en) | 1999-02-20 | 2000-08-24 | Merck Patent Gesellschaft Mit Beschraenkter Haftung | .beta.-alanine derivatives |
| DE19929410A1 (de) | 1999-06-26 | 2000-12-28 | Merck Patent Gmbh | Inhibitoren des Integrins avß6 |
| DE10028402A1 (de) | 2000-06-13 | 2001-12-20 | Merck Patent Gmbh | Pyridin-2-yl-aminoalkycarbonylglycyl-beta-alanin und Derivate |
| DE10112771A1 (de) | 2001-03-16 | 2002-09-26 | Merck Patent Gmbh | Inhibitoren des Integrins alpha¶v¶beta¶6¶ |
| EP2990410A1 (en) | 2004-08-10 | 2016-03-02 | Alnylam Pharmaceuticals Inc. | Chemically modified oligonucleotides |
| GB0520068D0 (en) | 2005-10-03 | 2005-11-09 | Cancer Res Technology | av peptide ligand |
| US20080213249A1 (en) * | 2006-07-07 | 2008-09-04 | The Scripps Research Insitute | Use of Retro-Aldol Reaction to Generate Reactive Vinyl Ketone for Attachment to Antibody Molecules by Michael Addition Reaction for Use in Immunostaining and Immunotargeting |
| US20110003858A1 (en) | 2006-09-04 | 2011-01-06 | Bergstroem Lena | Multimeric heterocyclic compounds useful as neutrophil elastase inhibitors |
| AR066984A1 (es) * | 2007-06-15 | 2009-09-23 | Novartis Ag | Inhibicion de la expresion de la subunidad alfa del canal epitelial de sodio (enac) por medio de arni (arn de interferencia) |
| WO2009069727A1 (ja) | 2007-11-28 | 2009-06-04 | Fujifilm Corporation | 生体高分子およびポリペプチドの化学修飾方法 |
| AU2009239491B2 (en) * | 2008-04-21 | 2014-07-17 | Lawrence Livermore National Security, Llc | Selective high-affinity polydentate ligands and methods of making such |
| CN102596922A (zh) * | 2009-10-06 | 2012-07-18 | 免疫基因公司 | 有效的缀合物和亲水性连接体 |
| GB0922014D0 (en) | 2009-12-17 | 2010-02-03 | Ge Healthcare Ltd | Novel integrin binders |
| US9161948B2 (en) * | 2011-05-05 | 2015-10-20 | Sarepta Therapeutics, Inc. | Peptide oligonucleotide conjugates |
| CN105017420B (zh) | 2012-02-17 | 2019-05-28 | 西雅图基因公司 | 针对整联蛋白αvβ6的抗体和使用该抗体治疗癌症 |
| JP2014029990A (ja) | 2012-06-29 | 2014-02-13 | Sharp Corp | 窒化物半導体装置の電極構造およびその製造方法並びに窒化物半導体電界効果トランジスタ |
| US8858913B2 (en) | 2012-08-27 | 2014-10-14 | Preeti Misra | Multimeric peptidomimetic fibrosis specific dual-modality probes |
| EP2913064A1 (en) * | 2014-02-26 | 2015-09-02 | celares GmbH | Branched drug-linker conjugates for the coupling to biological targeting molecules |
| WO2015160770A1 (en) | 2014-04-15 | 2015-10-22 | The Regents Of The University Of California | Bi-terminal pegylated integrin-binding peptides and methods of use thereof |
| WO2015179823A2 (en) | 2014-05-23 | 2015-11-26 | The California Institute For Biomedical Research | Lung localized inhibitors of alpha(v)beta 6 |
| US9803201B2 (en) | 2015-03-17 | 2017-10-31 | Arrowhead Pharmaceuticals, Inc. | Disulfide-containing alkyne linking agents |
| TWI761305B (zh) | 2015-05-29 | 2022-04-21 | 美商愛羅海德製藥公司 | 抑制Ｈｉｆ２α基因表現之組合物及方法 |
| JOP20190015A1 (ar) | 2016-08-04 | 2019-02-04 | Arrowhead Pharmaceuticals Inc | عوامل (ار ان ايه آي) لعدوى فيروس الالتهاب الكبدي الوبائي ب |
-
2018
- 2018-10-31 SG SG11202002967SA patent/SG11202002967SA/en unknown
- 2018-10-31 CN CN201880070813.4A patent/CN111526880A/zh active Pending
- 2018-10-31 UA UAA202003246A patent/UA128250C2/uk unknown
- 2018-10-31 PE PE2020000447A patent/PE20200938A1/es unknown
- 2018-10-31 CA CA3079402A patent/CA3079402A1/en active Pending
- 2018-10-31 MX MX2020004554A patent/MX2020004554A/es unknown
- 2018-10-31 KR KR1020257002849A patent/KR20250021615A/ko active Pending
- 2018-10-31 CR CR20200178A patent/CR20200178A/es unknown
- 2018-10-31 MY MYPI2020002120A patent/MY208467A/en unknown
- 2018-10-31 US US16/759,610 patent/US11597701B2/en active Active
- 2018-10-31 JP JP2020524155A patent/JP7445594B2/ja active Active
- 2018-10-31 TN TNP/2020/000059A patent/TN2020000059A1/en unknown
- 2018-10-31 EP EP18873120.2A patent/EP3703700A4/en active Pending
- 2018-10-31 IL IL274300A patent/IL274300B2/en unknown
- 2018-10-31 AU AU2018359515A patent/AU2018359515B2/en active Active
- 2018-10-31 WO PCT/US2018/058471 patent/WO2019089765A1/en not_active Ceased
- 2018-10-31 KR KR1020207015222A patent/KR102762143B1/ko active Active
- 2018-11-01 TW TW107138860A patent/TWI825039B/zh active
- 2018-11-01 TW TW112144459A patent/TWI914668B/zh active
-
2020
- 2020-04-13 PH PH12020550263A patent/PH12020550263A1/en unknown
- 2020-04-28 CL CL2020001125A patent/CL2020001125A1/es unknown
- 2020-05-03 SA SA520411899A patent/SA520411899B1/ar unknown
- 2020-05-06 JO JOJO/P/2020/0102A patent/JOP20200102B1/ar active
- 2020-06-01 EC ECSENADI202028090A patent/ECSP20028090A/es unknown
- 2020-07-13 MX MX2023007368A patent/MX2023007368A/es unknown
-
2023
- 2023-01-26 US US18/160,114 patent/US20240076270A1/en active Pending
- 2023-04-03 JP JP2023060316A patent/JP7758699B2/ja active Active
-
2024
- 2024-12-13 AU AU2024278418A patent/AU2024278418A1/en active Pending
-
2025
- 2025-06-25 JP JP2025107419A patent/JP2025129221A/ja active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| RU2748260C2 (ru) | РАСТВОРИМЫЕ С5аR АНТАГОНИСТЫ | |
| TWI825039B (zh) | 整合素配體及其用途 | |
| BR112019018230A2 (pt) | compostos de sulfamida cíclica e métodos de sua utilização | |
| CN109789146A (zh) | 趋化因子受体调节剂及其用途 | |
| BR112019021810A2 (pt) | Sistemas de liberação prolongada que compreendem ligantes não vestigiais | |
| JP2020531418A5 (enExample) | ||
| CN101142198A (zh) | 用于治疗疾病的异唑坎布雷它斯丁衍生物 | |
| JP2009524691A5 (enExample) | ||
| JP2021522269A5 (enExample) | ||
| TR201802093T4 (tr) | Terapötik terapilerde kullanım için akt inhibitör bileşiği ve abirateron kombinasyonu. | |
| CN104884057B (zh) | 大麻素受体介导的化合物 | |
| US20170305882A1 (en) | Benzyl substituted indazoles as bub1 kinase inhibitors | |
| CN102532198A (zh) | 抗病毒的次膦酸酯化合物 | |
| JP2021516271A5 (enExample) | ||
| JP2013525414A5 (enExample) | ||
| HU229155B1 (en) | Propanoic acid derivatives that inhibit the binding of integrins to their receptors | |
| TW200524903A (en) | Quinazoline derivatives | |
| JP2018525425A5 (enExample) | ||
| US20180042905A1 (en) | Methods of treating hepatitis b virus | |
| JPH06505265A (ja) | ヒスタミンｈ↓３受容体に対する作動的または拮抗的活性を有するイミダゾール誘導体 | |
| EP4642782A2 (en) | Alpha-v-beta-8 integrin inhibitors and uses thereof | |
| JP2022544536A5 (enExample) | ||
| CN104546819A (zh) | 二咖啡酰奎宁酸在治疗系统性自身免疫性疾病中的用途 | |
| JP2018502851A (ja) | アムホテリシンｂの尿素誘導体の簡便な合成法 | |
| TW200838561A (en) | Posaconazole polymer conjugates and methods of treatment using posaconazole and polymer conjugates thereof |